Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shawn Gugliandolo
Observed names:
Gugliandolo, Shawn,
SHAWN GUGLIANDOLO
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0000-0002-9656-4171
Observed ORCID:
0000-0002-9656-4171
OpenAlex ID:
A5067554949
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes
2023
·
Francesca Cinti
, Lucia Leccisotti
, et al.
·
Cardiovascular Diabetology
·
84
PDF
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
2022
·
Lucia Leccisotti
, Francesca Cinti
, et al.
·
Cardiovascular Diabetology
·
74
PDF
SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives
2024
·
Cassandra Morciano
, Shawn Gugliandolo
, et al.
·
Cardiovascular Diabetology
·
57
PDF
The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?
2025
·
Francesca Cinti
, Renzo Laborante
, et al.
·
Cardiovascular Diabetology
·
44
PDF
Erythrocyte Membrane Fluidity and Omega-3 Fatty Acid Intake: Current Outlook and Perspectives for a Novel, Nutritionally Modifiable Cardiovascular Risk Factor
2024
·
Umberto Capece
, Shawn Gugliandolo
, et al.
·
Nutrients
·
19
PDF
Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study
2025
·
Francesca Cinti
, Cassandra Morciano
, et al.
·
Cardiovascular Diabetology
·
10
PDF
Illuminating Glucose: How to Unveil Organ‐Specific Insulin Resistance and Guide Metabolic Strategies in Diabetes
2026
·
Shawn Gugliandolo
, Cassandra Morciano
, et al.
·
Diabetes/Metabolism Research and Reviews
·
4
In humans increase in intrapancreatic adipose tissue predicts beta-cell dedifferentiation score before diabetes onset: A pilot study
2025
·
Francesca Cinti
, Teresa Mezza
, et al.
·
Diabetes Research and Clinical Practice
·
4
PDF
A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study
2026
·
Shawn Gugliandolo
, Cassandra Morciano
, et al.
·
Diabetes Obesity and Metabolism
·
2
Impact of the Friedewald equation vs 2 validated equations on LDL-C estimates and goal achievement in hospitalized patients with diabetes
2026
·
Umberto Capece
, Chiara Iacomini
, et al.
·
Journal of clinical lipidology
·
1
Corrigendum to “In humans increase in intrapancreatic adipose tissue predicts beta-cell dedifferentiation score before diabetes onset: A pilot study” [Diabetes Res. Clin. Pr. 221 (2025) MS N. 112029]
2025
·
Francesca Cinti
, Teresa Mezza
, et al.
·
Diabetes Research and Clinical Practice
·
1
PDF
140-OR: The Coronary Flow Reserve Increase after Dapagliflozin Treatment in Patients with Type 2 Diabetes Is Maintained after Four Years—A Four-Year DAPAHEART Follow-up Study
2024
·
CASSANDRA MORCIANO
, FRANCESCA CINTI
, et al.
·
Diabetes
·
1
1535-P: Type 2 Diabetes Remission after Roux-en-Y Gastric Bypass Is Related to a Reduction of Pancreatic Noradrenergic Innervation and Beta-Cell Redifferentiation
2024
·
FRANCESCA CINTI
, ADRIANA AVOLIO
, et al.
·
Diabetes
·
1
Response to “Methodological Considerations in Interpreting Renal [ 18 F ] FDG ‐ PET After Short‐Term Dapagliflozin Treatment”
2026
·
Shawn Gugliandolo
, Patricia Iozzo
, et al.
·
Diabetes Obesity and Metabolism
PDF
The role of noradrenergic innervation and β-cell dedifferentiation in diabetes
2026
·
Adriana Avolio
, Cassandra Morciano
, et al.
·
Trends in Endocrinology and Metabolism
Modifiable Risk Factors
2026
·
Shawn Gugliandolo
, Andrea Giaccari
, et al.
·
CRC Press eBooks
128-OR: The Significant Reduction in Epicardial Adipose Tissue Thickness after Dapagliflozin Treatment Is Preserved and Even Increased after Four Years—The DAPAHEART Four-Year Follow-up Study
2025
·
CASSANDRA MORCIANO
, SHAWN GUGLIANDOLO
, et al.
·
Diabetes
127-OR: A Four-Week Treatment with Dapagliflozin Reduces Insulin-Stimulated Renal Glucose Uptake
2025
·
SHAWN GUGLIANDOLO
, CASSANDRA MORCIANO
, et al.
·
Diabetes
1068-P: Reassessing Insulin Therapy In Diabetes of the Exocrine Pancreas—A Pilot Study
2024
·
GEA CICCARELLI
, GIANFRANCO DI GIUSEPPE
, et al.
·
Diabetes
Real-world evidence evaluation of LDL-C among hospitalized patients: a population-based observational study in the timeframe 2021-2022
2024
·
Umberto Capece
, Chiara Iacomini
, et al.
·
European Atherosclerosis Journal
PDF
1301-P: Glucagon Stimulation Test—Is It Time for an Easy Interpretation Proposal?
2023
·
ALESSANDRO RIZZI
, LINDA TARTAGLIONE
, et al.
·
Diabetes
Show more works
View as search
Works count:
26
Citation count:
302
H-index:
6
I10-index:
6
Year
Topic
Type